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Abstract
Calmodulin-dependent protein kinase IV (CaMKIV) is a key mediator of Ca2-induced gene expression. This serine/
threonine kinase is itself activated by a calmodulin kinase kinase. In the present contribution the gene structure, regulation of
activity, the role in Ca2-dependent gene expression, and the hormonal induction and controlled expression of CaMKIV
during tissue development are reviewed. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Ca2, as one of the most versatile second messen-
gers involved in basic cellular processes such as
muscle contraction, excitation secretion coupling,
gene expression, proliferation, di¡erentiation, and
apoptosis [1,2], plays its pivotal role through a spe-
ci¢c class of proteins, the so-called EF-hand type
Ca2-binding proteins [3]. The most prominent rep-
resentative of the intracellular Ca2-binding proteins
is calmodulin (CaM) [4] which binds to and activates
a great variety of enzymes, such as nucleotide cy-
clases and phosphodiesterases, nitric oxide synthases
and plasma membrane calcium pumps (for review see
[5,6]), but most notably a class of di¡erent protein
kinases and phosphatase(s), i.e., CaM-kinases and
calcineurin [7,8]. Since protein kinases and phospha-
tases are key modulators of cellular regulatory proc-
esses, it is not surprising that CaM-kinases are in-
volved in the regulation of such central processes as
neurotransmitter release, muscle contraction, cell
proliferation and gene expression (for reviews see
[5,9,10]). Six di¡erent CaM-dependent kinases are
known to date, all belonging to the class of enzymes
phosphorylating serine^threonine residues. The tar-
gets can be either of multiple sources (e.g., CaM-
kinase I, II and IV) or dedicated to single substrates
(e.g., myosin light chain kinase, phosphorylase ki-
nase or CaM-kinase III).
The CaM-dependent protein kinase IV (CaMKIV)
was ¢rst described as being particularly abundant in
the granular cells of the cerebellum [11] which was
the reason for its original name ‘CaM-kinase Gr’
[11]. Later, the protein was renamed CaM-kinase
IV (CaMKIV) [12,13]. In contrast to CaMKII or
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calcineurin which are ubiquitously expressed, CaM-
KIV is restricted in expression to nervous tissues [12],
to the thymus, particularly T-lymphocytes [14] and,
to a somewhat lower extent, to the spleen and to
testis. In all other tissues examined CaMKIV re-
mained undetectable [10,11,15,16]. Here I will sum-
marize recent results concerning the gene structure of
the enzyme, the regulation of CaMKIV activity by a
kinase cascade, its importance for calcium-dependent
gene expression, and its induction during tissue de-
velopment.
2. The gene structure of CaMKIV
CaMKIV is expressed in two spliced isoforms of
Mr 65 000 (K) and of Mr 67 000 (L), of which the
latter is found mainly in the cerebellum [17]. The
two isoforms di¡er only by the presence of a 28-
amino acid N-terminal extension on the L-isoform
[18]. The primary structure has been determined for
di¡erent mammalian species showing a high degree
of similarity [12,13,18^20]. The amino acid sequences
of the regulatory and catalytic domains of CaMKIV
are highly similar to corresponding regions of CaM-
KII, but the overall homology between the two en-
zymes is less than 50%. Recently, the gene structure
of CaMKIV has been reported [21]. The length of
the gene is 42 kb of DNA, divided into 12 exons and
11 introns. A remarkable ¢nding was that the last
169 amino acids of CaMKIV were identical to the
entire coding sequence of another calmodulin-bind-
ing protein, calspermin, which is exclusively ex-
pressed in meiotic male germ cells of a number of
mammalian species, but for which a function is un-
known to date [12,21]. The promoter region of cal-
spermin could be identi¢ed in the tenth intron of the
CaMKIV gene [21]. Crucial for the regulation of ex-
pression for calspermin were two cAMP-dependent
protein kinase responsive elements (CRE) [22] which
are also known to be important for Ca2-dependent
gene expression (see below), and which are located
within the identi¢ed promoter region. It could be
further demonstrated that these elements bound
CREB, the CRE-binding protein, or CREMd, the
testis-speci¢c CREB-homologous transcriptional ac-
tivator, which upon phosphorylation by protein kin-
ase A (PKA) could stimulate transcription of calsper-
min by a factor of 10 [22]. In this context it is of
interest to note that in CREM3=3 mice the males are
sterile due to a inhibition of spermatogenesis at
meiosis, and calspermin is not expressed [23,24]. As
it will be discussed in detail later, CREB as well as
the homologous CREMd can be phosphorylated by
CaMKIV at the same serine residue recognized by
PKA, thereby activating it [22,25,26] which would
lead to the intriguing possibility that activation of
CREMd in the testis would be mediated by CaM-
KIV, i.e., CaMKIV would regulate the expression
of its own gene product, calspermin.
3. Regulation of activity
The regulation of the activity of CaMKIV is a
rather complex process and involves three major
steps:
1. Binding of Ca2/CaM to the enzyme
2. Phosphorylation of threonine196 by a calmodulin-
dependent kinase kinase
3. Autophosphorylation of serine residue(s) at the N-
terminus of the enzyme
Protein kinases are known to be maintained in an
inhibited state by an autoinhibitory segment. This
principle is also true for calmodulin-dependent pro-
tein kinases as well as for other calmodulin-depend-
ent enzymes (for a review see [5]). Activation of
calmodulin-dependent kinases involves binding of
Ca2-bound calmodulin to a binding domain in the
regulatory segment of the enzyme, containing also
the autoinhibitory sequence which in the resting state
interacts with the catalytic domain. Due to the inter-
action of calmodulin with its binding domain the
autoinhibitory segment is removed from the catalytic
core, exposing the active site of the kinase for bind-
ing of the substrate and subsequent phosphorylation
[27]. The boundary between the autoinhibitory seg-
ment and the calmodulin-binding domain is often
not clearly de¢ned, sometimes they are adjacent to
each other, sometimes they are overlapping, but
there are also cases in which the autoinhibitory se-
quence is part of the calmodulin-binding domain
(see, e.g., [6]). With respect to CaMKIV, truncation
experiments carried out in di¡erent laboratories seem
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to indicate that the autoinhibitory region minimally
includes residues 305^317 [28,29]. Adjacent to it, res-
idues 319^335 can be identi¢ed as the calmodulin-
binding domain which is highly homologous to oth-
er, well characterized calmodulin-binding sites (see
Fig. 1). The binding domain of CaMKIV contains
a serine residue at position 332 which upon phos-
phorylation prevents calmodulin binding [30]. De-
tailed structural studies of calmodulin complexed to
peptides corresponding to di¡erent binding domains
[31^34] revealed the interesting observation that two
hydrophobic residues spaced by either 8 or 12 amino
acids are essential anchors to wrap calmodulin
around the binding domain, and that the ¢rst anchor
residue often is a tryptophan (see Fig. 1; for review
see [35]). Based on the recently published crystal
structure of apo-calmodulin kinase I [36] which
shows the tryptophan W303 exposed to the solvent,
it could be suggested that the accessibility of the
tryptophan is essential for calmodulin binding to
the target [34,36]. This conclusion was recently cor-
roborated by Matsushita and Nairn [37], who re-
ported that mutation of W303 to a serine residue
reduced the a⁄nity of CaMKI for calmodulin by a
factor of 3000. Interestingly, in the CaM-binding do-
main of CaMKIV the ¢rst anchor residue is not a
tryptophan but a leucine (see Fig. 1). The interaction
between calmodulin and the corresponding peptide
of the binding domain of either CaMKI or CaMKIV
should be similar to those determined for the pepti-
des of MLCK complexed to calmodulin [31,32], but
di¡erent to the complex with the calmodulin-binding
peptide of CaMKII [33], since in the binding domain
of CaMKI and CaMKIV the two hydrophobic an-
chor residues are spaced by 12, not by 8 positions as
in CaMKII.
Such a di¡erence in interaction between calmodu-
lin and CaMKII on one hand and CaMKI and
CaMKIV on the other could also be re£ected by
the di¡erence in their activation properties. CaMKII,
the most detailed studied example of a calmodulin-
dependent protein kinase, is a multisubunit, homo-
or hetero-oligomer enzyme complex which is acti-
vated by autophosphorylation between two neigh-
bouring subunits [38]. On the other hand, CaMKI
and CaMKIV do not seem to multimerize, and
both enzymes are activated by a calmodulin-depend-
ent kinase kinase (CaMKK), whether both are acti-
vated by the same kinase kinase or by di¡erent en-
zymes is not entirely clear at the moment. Originally,
it was thought that CaMKIV was autophosphoryl-
ated at Thr196, similar to CaMKII, but studies on
recombinant CaMKIV demonstrated that the auto-
phosphorylation process was very slow [29], which
could be signi¢cantly enhanced by a brain extract
[29,39]. This ¢nding led to the discovery of the
CaMKK which, at least in vitro, can phosphorylate
and activate both, CaMKI and CaMKIV. In CaM-
KIV, the critical residue phosphorylated by CaMKK
is Thr196 which is located in the activation loop of
the kinase [40,41]. Accessibility of Thr196 is brought
about by the binding of calmodulin, i.e., binding of
calmodulin not only releases autoinhibition of CaM-
KIV, but also enables the enzyme to be phospho-
rylated at this critical residue. This phosphorylation
results in a 10^20-fold activation of CaMKIV
[42,43].
As indicated before, there is a third level of acti-
vation of CaMKIV concerning phosphorylation of
serine residues at the N-terminus of CaMKIV. In a
detailed study, Chatila et al. [44] could demonstrate
that Ser11 and Ser12 could be autophosphorylated in
a slow process as indicated before, but the latter
could be considerably enhanced by the phosphoryla-
tion of Thr196 by CaMKK [44].
Fig. 1. Amino acid sequences of di¡erent calmodulin-binding
domains using the common one-letter code. Bold letters indicate
the proposed hydrophobic anchor residues. The sequences have
been obtained from the following references: CaMKIV, Bland
et al. [20]; CaMKI, Piccioto et al. [69]; CaMKII, Meador et al.
[33]; skMLCK (M13), Ikura et al. [31]; smMLCK (R20), Lu-
kas et al. [70]; PMCA (C28W), Verma et al. [71].
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4. CaMKIV and Ca2-dependent gene expression
One of the consequences of elevated calcium in the
cell, especially in the nucleus, is the induction of gene
expression [45]. Since transcription factors such as
CREB [25,26,46], CREMd [22,25], ATF-1 [47], SRF
[48], and ETS-1 [49,50] are among the best substrates
for CaMKIV, and CaMKIV has been localized to
the nucleus [25,51,52], the enzyme could have direct
access to transcription factors to regulate their func-
tion in a Ca2-dependent manner. Thus it has been
shown in di¡erent cell lines that CaMKIV is involved
in the regulation of expression of immediate early
genes (IEGs) either through CREB [25,26,53,54] or
through SRF [48].
Originally, CREB was identi¢ed by Gonzalez and
Montminy [55] as a factor induced in a cAMP-de-
pendent process which could be activated by PKA-
dependent phosphorylation. Later studies provided
evidence that this transcription factor could also be
activated in a Ca2-dependent manner [45,46]. Nu-
merous studies demonstrated that all kinases activat-
ing CREB phosphorylated the transcription factor at
the same serine residue: Ser133 [25,26,46,54]. First
studies investigating which CaM-dependent kinase
could play a role as a CREB-kinase suggested that
this may be CaMKII [46], but subsequent investiga-
tions provided evidence that CaMKIV is the true
CREB-Kinase inducing Ca2-dependent gene expres-
sion [29,54]. In fact, Sun et al. [54] demonstrated in a
detailed phosphopeptide analysis that CaMKII not
only phosphorylated CREB at Ser133, but also at
Ser142, and that the latter phosphorylation had an
inhibitory in£uence on gene expression, and was
dominant over Ser133 phosphorylation.
IEGs such as c-fos are a group of genes which are
rapidly and transiently activated by growth factors
and other stimulatory mechanisms. A number of
IEGs code for transcription factors like members of
the fos and jun families, which dimerize to form the
transcription regulatory complex AP-1. There is am-
ple evidence that several signal transduction path-
ways can enhance the expression of c-fos, the best
characterized system modulating the expression
through the transcription factor CREB [56]. Re-
cently, we provided evidence that CaMKIV could
be involved in the regulation of c-fos expression in
a primary fetal brain tissue culture system through
the phosphorylation of CREB, since CaMKIV was
present in those tissues only after induction by the
thyroid hormone T3 (see below) [57], and Ca2-de-
pendent stimulation of c-fos expression was down-
regulated in the absence of CaMKIV, i.e., in the
absence of T3 [58]. In this context it is also of interest
that Matthews et al. [25] provided evidence that in
transfected cells only CaMKIV, but not CaMKII,
was able to transactivate a CRE-containing reporter
gene in transient expression assays through the phos-
phorylation of CREB, since only CaMKIV could
translocate to the nucleus [25]. On the other hand,
phosphorylation of CREB by CaMKII could have
an inhibitory e¡ect on CREB-dependent gene expres-
sion, as suggested by Sun et al. [54], which could
explain the recent ¢nding of Nghiem et al. [59] who
reported that in Jurkat T cells transfected with a
constitutively active mutant of CaMKII, expression
of interleukin-2 (IL-2) was downregulated by more
than 90%. Since IL-2 expression is mainly controlled
via the transcription factors NFAT and AP-1, the
latter being a heterodimer of c-Fos and c-Jun, it
could be suggested that downregulation of IL-2
could occur through inhibition of CREB controlling
c-Fos expression. It is interesting that Nghiem et al.
[59] indeed found that CaMKII signi¢cantly de-
creased stimulated transcription from AP-1. In Fig.
2 a schematic view of the di¡erent possible signal
transduction pathways is provided, which may con-
verge at the phosphorylation and subsequent activa-
tion or inhibition of CREB and possible consequen-
ces for the regulation of gene expression.
5. Induction of CaMKIV during development
Thyroid hormones such as 3,3P,5-triiodo-L-thyro-
nine (T3) have been shown to be required for normal
growth and di¡erentiation of the mammalian brain
[60,61]. T3 acts through a speci¢c receptor recogniz-
ing regulatory elements of the expressed gene, as has
been described for other members of the superfamily
of steroid/thyroid hormone receptors [62]. In a recent
report we provided evidence for the speci¢c induc-
tion of CaMKIV by T3 in a time- and concentration-
dependent manner at a very early stage of brain dif-
ferentiation, using a fetal rat telencephalon primary
cell culture system which can grow and di¡erentiate
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under chemically de¢ned conditions [57]. The induc-
tion was T3-speci¢c, i.e., the expression of the en-
zyme could not be induced by either reverse T3
(rT3) or retinoic acid. The expression of CaMKIV
was regulated on both, the transcriptional and the
translational level, since both the addition of actino-
mycin D as well as cycloheximide to the cultural
medium could prevent the T3-dependent induction
of the enzyme. Whether this T3-dependent regulation
is due to a direct interaction of the T3-receptor with
a responsive element of the CaMKIV gene or
whether the e¡ect is indirect remains to be deter-
mined, but since the T3-speci¢c induction of CaM-
KIV could also be observed on the mRNA level, this
observation could be indicative for a T3-receptor de-
pendent regulation. In this respect it is of interest
that in a recent abstract [63] it was reported that in
a mouse embryonic stem cell derived neuronal cul-
ture system the expression of CaMKIV was strictly
dependent on the presence of the thyroid hormone
receptor, i.e., such a T3-dependent response was not
observable in embryonic stem cells derived from
TRK3=3 mice (during embryonal development only
TRK is expressed).
Apart from the nervous tissue, CaMKIV is mainly
expressed in the immune system [64]. Recently, we
reported that in a murine E14 fetal thymic culture
system, CaMKIV was not detectable, even after sev-
eral days of culture if a minimal culture medium
lacking fetal calf serum was used [65]. However, on
addition of fetal calf serum, the expression of CaM-
KIV could be speci¢cally induced. Quantitation of
CaMKIV at di¡erent days of gestation provided evi-
dence that also in rat thymus, CaMKIV could not be
detected before day E16, and that expression of the
enzyme was fully upregulated at day E18. Further-
more, analysis of thymocyte subsets representing dif-
ferent developmental stages revealed that during
adult thymic T-cell development the expression of
CaMKIV was tightly regulated [65] indicating that
CaMKIV was not expressed during the early stages
of T-cell development, but started to be detectable
¢rst at the stage CD253/443. The highest concentra-
tion was observed in the CD25/44 cells [65], in
agreement with observations reported by Hanissian
et al. [64].
Maturation of T cells in the thymus is a complex
developmental process taking almost 3 weeks from a
pluripotent stem cell to a fully developed mature
CD4 or CD8 SP cell, during which time lineage
commitment, gene rearrangement, expression of the
T-cell receptor, and selection processes take place.
Anderson et al. [66] recently demonstrated that
transgenic mice expressing a catalytically inactive
form of CaMKIV not only were hampered in T-
cell activation, but also exhibited a signi¢cant defect
in thymic cellularity, indicating that CaMKIV may
play a critical role in T-cell maturation. Therefore,
the authors discussed the possibility that defective
CaMKIV expression could prevent the maturation
of DN into DP cells. In this respect it is interesting
to note that in a recent communication CREB3/3
mice were reported to exhibit a defect in T-cell devel-
opment [67] which also showed a characteristic re-
duction in thymic cellularity. Thymocytes of these
CREB de¢cient cells accumulate at the immature
double-negative stage (CD253443), unable to prog-
ress into the double-positive stage (CD2544), i.e.,
the transition during which CaMKIV reaches its
Fig. 2. Schematic view of di¡erent signal transduction pathways
converging on CREB. The scheme summarizes the in£uence of
di¡erent kinases on CREB phosphorylation involved in di¡er-
ent Ca2-dependent pathways of gene expression as illustrated
by c-fos and subsequently by IL-2 expression (see also [25,46]).
AP-1, activator protein 1; CaMKII, -IV, calmodulin-dependent
kinase II, IV; CaMKK, calmodulin-dependent kinase kinase;
CREB, cAMP-dependent regulatory element binding protein;
NFAT, nuclear factor of activated T-cells ; NFATRE, NFAT
regulatory element; PKA, cAMP-dependent protein kinase. (+)
Indicates upregulation and (3) downregulation of the c-fos ex-
pression.
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highest expression during T-cell development [65].
Thus it appears that the transcription factor CREB
and its activating kinase CaMKIV are essential ele-
ments for T-cell development.
6. Conclusions and perspectives
In this review I have summarized various aspects
of the properties of the calmodulin-dependent pro-
tein kinase IV (CaMKIV). This multifunctional en-
zyme which phosphorylates its substrates at serine or
threonine residues is activated by a multistep proc-
ess:
1. Binding of Ca2/CaM
2. Phosphorylation by a CaM-dependent kinase ki-
nase
3. Autophosphorylation of N-terminal serine resi-
dues
Activated CaMKIV is a key mediator of Ca2-in-
duced gene expression, mainly regulated via the
phosphorylation of transcription factors such as
CREB. The enzyme plays its major role during acti-
vation and development of neurons and T cells. The
critical function played by CaMKIV regulating
Ca2-dependent gene expression may be re£ected
by the observation that the enzyme itself is under
tight regulatory control: during development of neu-
rons or T cells the expression of CaMKIV is hormo-
nally induced and the level of CaMKIV expression
during T-cell development is tightly controlled. In
this respect a recent report by Westphal et al. [68]
may shed some light on a possible mechanism for a
coordinated control of activation and deactivation of
CaMKIV. Westphal et al. [68] identi¢ed in T cells
and in brain a stoichiometric complex between CaM-
KIV and the serine^threonine phosphatase 2A
(PP2A) which may function as a negative regulator
of CaMKIV. PP2A, on the other hand, could be
inhibited by small t-antigen which in turn increased
CREB-mediated transcription by CaMKIV. Thus it
seems likely that the level of expression and the state
of activation of CaMKIV are tightly controlled,
thereby regulating the duration of immediate early
gene expression such as c-fos. Future experiments
will hopefully unravel details of the mechanisms of
such a tightly controlled network.
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